Spyre Therapeutics (SYRE) analyst forecast and price target
Analyst forecast
Consensus of 15 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BTIG | Maintained | Buy | $121.00 from $132.00 | Aug 26, 2026 |
| Wedbush | Maintained | Outperform | $123.00 from $130.00 | Aug 26, 2026 |
| Deutsche Bank | Maintained | Buy | $127.00 from $135.00 | Aug 26, 2026 |
| BTIG | Maintained | Buy | $132.00 from $112.00 | Aug 11, 2026 |
| Wedbush | Maintained | Outperform | $130.00 from $100.00 | Aug 5, 2026 |
| Guggenheim | Maintained | Buy | $130.00 from $115.00 | Aug 5, 2026 |
| Wells Fargo | Maintained | Overweight | $115.00 from $90.00 | Aug 5, 2026 |
| Wolfe Research | Downgraded | Outperform → Peer Perform | — | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $120.00 from $84.00 | Jul 13, 2026 |
| Deutsche Bank | Maintained | Buy | $135.00 from $115.00 | Jun 23, 2026 |
| BTIG | Maintained | Buy | $112.00 from $98.00 | Jun 15, 2026 |
| Deutsche Bank | Maintained | Buy | $115.00 from $102.00 | Jun 4, 2026 |
| Stifel | Maintained | Buy | $107.00 from $92.00 | May 6, 2026 |
| Citigroup | Maintained | Buy | $97.00 from $64.00 | May 6, 2026 |
| Jones Trading | Maintained | Buy | $95.00 from $64.00 | Apr 17, 2026 |
| Deutsche Bank | Maintained | Buy | $88.00 from $55.00 | Apr 14, 2026 |
| Wedbush | Maintained | Outperform | $80.00 from $65.00 | Apr 14, 2026 |
| Wells Fargo | Maintained | Overweight | $90.00 from $50.00 | Apr 14, 2026 |
| Baird | Maintained | Outperform | $90.00 from $65.00 | Apr 14, 2026 |
| Raymond James | Initiated Coverage | Strong Buy | $80.00 | Apr 14, 2026 |
Frequently asked questions
What is the price target for SYRE stock?
The average 12-month analyst price target for Spyre Therapeutics (SYRE) is $122.67, with a high estimate of $130.00 and a low of $115.00, across 6 analysts.
Is SYRE a buy, sell, or hold?
Analysts covering Spyre Therapeutics currently average a Buy rating: 14 buy, 1 hold and 0 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for SYRE?
The average price target of $122.67 implies 39.60% upside from the last price of $87.87.
What is the latest analyst rating on SYRE?
On Aug 26, 2026, BTIG maintained Spyre Therapeutics at Buy with a price target of $121.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.